Navigation Links
Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
Date:9/22/2010

deliver up to a full year of therapy from a single ITCA 650 insertion. Unlike other extended delivery technologies, such as polymers or albumin fusions, DUROS delivery allows for steady state drug delivery upon insertion and near immediate withdrawal of therapy, if required. ITCA 650 is an investigational new drug and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, has been approved in the U.S., Europe and many other markets and is currently marketed as a twice-daily self-injection therapy for type 2 diabetes.

About Type 2 DiabetesAccording to the National Institutes of Health (NIH), "Approximately 23.6 million Americans have type 2 diabetes, which represents 7.8 percent of the U.S. population and about 1/4 of them don't even know it.  In addition, we now know that at least another 57 million Americans have 'pre-diabetes.'" Diabetes is conservatively estimated to be the seventh leading cause of death in the U.S.  Minority populations are disproportionately affected, particularly African Americans and Hispanics. For example, African Americans are 1.8 times more likely to develop type 2 diabetes compared to non-Hispanic whites.

According to the Centers for Disease Control and Prevention (CDC), the rate of new cases of type 2 diabetes has nearly doubled in the U.S. in the last decade with these new cases mirroring an increase in obesity rates - a leading cause of type 2 diabetes.

About IntarciaIntarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the efficacy, convenience and tolerability of drug therapies. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above body temperature and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. Intarcia is pur
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
2. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Moms are ready to live the "measured life" ... kids, according to the results of the BabyCenter® U.S. ... for Moms, the latest installment in BabyCenter,s 21 st ... and parenting web and mobile destination worldwide, conducted the ... say they can,t think of a reason not to ...
(Date:10/22/2014)... 22, 2014 AVACEN Medical announced today that ... (k) OTC clearance by the U.S. Food and Drug ... marketed over the Internet for: the temporary relief ... minor strains and sprains . Logo - ... (MSRP $2495) is a sophisticated medical device incorporating over ...
(Date:10/22/2014)... , Oct. 22, 2014  CryoLife, Inc. (NYSE: ... processing company focused on cardiac and vascular surgery, announced ... and Chief Executive Officer, has been elected to the ... Steven G. Anderson , Executive Chairman of ... proven to be an excellent leader who is well ...
Breaking Medicine Technology:BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3
... A new report criticizes the US Drug Enforcement ... addictive medications without a valid prescription requirement. ... , analyzes the DEA,s implementation of the Ryan Haight Online ... named after an 18-year old who died after purchasing Vicodin ...
... VIEW, Calif., June 8, 2011 Edison Pharmaceuticals, ... Drug Administration has granted orphan drug designation to ... diseases. Today, these mitochondrial diseases affect an estimated ... passed in 1982, provides incentives for companies to ...
Cached Medicine Technology:Report Criticizes DEA for Failing to Address Online Pharmacy Problem 2Edison Pharmaceuticals Announces FDA Grants EPI-743 Orphan Drug Designation 2
(Date:10/22/2014)... Amy Norton HealthDay ... Headlines remain riveted on the three Ebola cases in Dallas. ... bigger health threat to Americans. President Barack Obama on ... to the virus, which has infected two Dallas nurses who ... month at Texas Health Presbyterian Hospital. But the U.S. ...
(Date:10/22/2014)... October 22, 2014 Shriners Hospitals for ... will change the current location of Shriners Hospitals for ... Limestone across from the University of Kentucky Albert B. ... ambulatory care center, owned and operated by Shriners Hospitals ... needs of children and their families well into the ...
(Date:10/22/2014)... California (PRWEB) October 22, 2014 Hay House ... Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written ... of Yoga & Recovery. This book is meant to ... in a life of recovery. , Recovery 2.0 is ... 12 Steps; Recovery 2.0 is a guide for what comes ...
(Date:10/22/2014)... Grants Pass, OR (PRWEB) October 22, 2014 ... while Southern California’s fresh water supply runs dangerously low, ... climate change. Southern Oregon’s rivers, despite the lowest mountain ... fast even in late summer and early autumn.* That ... Urness, authors of the new book “Hiking Southern Oregon,” ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
Breaking Medicine News(10 mins):Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2
... MOORESVILLE, N.C., Sept. 2 Anpath Group, Inc. (OTC Bulletin Board: ... has joined the Board of Directors. , , ... disease care, specifically with HIV treatment and immunology. Currently he ... American Academy of HIV Medicine. In 2000, he founded his ...
... , THE WOODLANDS, Texas, Sept. 2 eCardio ... America,s fastest-growing private companies - the Inc. 500. Inc. magazine ... top quarter as #117 with a three-year sales growth of 1,424%. ... going to change the world, look at the Inc. 500," said Inc. ...
... , , , BARCELONA, Spain, ... drug-drug interactions, versus other statins, as evidenced by a new study ... pharmacokinetics of LIVALO in healthy volunteers. The data were presented by ... Spain. , , Many statins currently prescribed in ...
... , Agreement Will Advance Research Connecting ... , MORGANTOWN, W.V., Sept. 2 The ... a group of neurological specialists (Brain Injury Group) to examine ... trauma, and strokes and BRNI,s research. Together, they will explore ...
... LONDON, Sept. 2 Although most hospitals in Europe ... have a fully integrated and functional hospital information systems (HIS) ... in Europe varied from about 73.0 per cent in Italy ... pressures on the government and regulatory authorities to garner more ...
... , ... the Convenience of Desktop Fax and Print-to-Fax Capabilities to Epygi,s SMB and Small/Medium Enterprise ... ... Technologies, Ltd., a worldwide provider of small to medium business IP PBX telephone systems, ...
Cached Medicine News:Health News:Dr. William J. Robbins Joins Anpath Group, Inc. Board of Directors 2Health News:Dr. William J. Robbins Joins Anpath Group, Inc. Board of Directors 3Health News:eCardio Included on Inc. Magazine's 28th Annual List of America's Fastest-Growing Private Companies -- the Inc. 500 2Health News:Study Shows LIVALO(R) is not Affected by Co-Administration of Itraconazole 2Health News:Study Shows LIVALO(R) is not Affected by Co-Administration of Itraconazole 3Health News:Study Shows LIVALO(R) is not Affected by Co-Administration of Itraconazole 4Health News:Study Shows LIVALO(R) is not Affected by Co-Administration of Itraconazole 5Health News:Blanchette Rockefeller Neurosciences Institute to Collaborate with Top Brain Injury Group 2Health News:Blanchette Rockefeller Neurosciences Institute to Collaborate with Top Brain Injury Group 3Health News:Added Investment Into Healthcare By the Government Drives Growth in the European Hospital Information Systems Market, Notes Frost & Sullivan 2Health News:Added Investment Into Healthcare By the Government Drives Growth in the European Hospital Information Systems Market, Notes Frost & Sullivan 3Health News:Epygi Technologies Partners with FaxBack to Incorporate Microsoft Fax into Epygi's VoIP Phone Systems 2Health News:Epygi Technologies Partners with FaxBack to Incorporate Microsoft Fax into Epygi's VoIP Phone Systems 3Health News:Epygi Technologies Partners with FaxBack to Incorporate Microsoft Fax into Epygi's VoIP Phone Systems 4
... patients with a diseased heart, the only therapy solution ... transplant. However, donor organs are not always readily available. ... are on the waiting list for a donor organ. ... save the life of a patient. On the one ...
The SonoSite MicroMaxx gives you big machine performance in a lightweight package. This laptop-sized, durable unit represents the technology crossover point between hand-carried ultrasound and larger...
... The Nichols Advantage® 25-Hydroxyvitamin D Assay is ... Specialty System. The Nichols Advantage® 25-Hydroxyvitamin D ... of 25-,hydroxyvitamin D (25-OH-D) and other hydroxylated ... plasma to be used as an aid ...
... The CoaguChek Pro is a ... of the coagulation parameters PT, APTT, ... professional use in hospitals and medical ... e.g., in cardiac catheterization laboratories, and ...
Medicine Products: